Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · GHK-CuWeak / none
Microenvironment-responsive injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy of radiation-induced skin injury.
This is a biomaterials study, tested in cells and in animals, in which GHK-Cu is one component of an engineered injectable hydrogel built to manage radiation-induced skin injury. The design is a two-stage system: superoxide-dismutase-mimicking carbon dots release first in the acidic wound to mop up reactive oxygen species, then GHK-Cu releases more slowly to support tissue repair. The researchers report the hydrogel reduced oxidative damage and inflammation and sped skin-wound closure in their in-vitro and in-vivo tests. Two things to keep in mind. First, GHK-Cu's contribution cannot be isolated from the carbon dots and the chitosan-hyaluronic-acid matrix - this is a combination system, so any benefit belongs to the platform, not the peptide alone. Second, these are preclinical results; human data would be needed before clinical conclusions could be drawn. For GHK-Cu specifically, this aligns with its established topical/local wound-repair and anti-inflammatory profile, but adds no human evidence for systemic use.
Bioactive materialsn=—AnimalSep 1, 2026 - Study · GHK-CuWeak / none
Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healing.
This preclinical materials study builds a glucose-oxidase-loaded hydrogel incorporating the copper tripeptide GHK-Cu for infected diabetic wounds via a two-step (cascade) reaction: glucose oxidase lowers local glucose and makes hydrogen peroxide, then copper from GHK-Cu breaks that peroxide down to release oxygen and relieve wound low-oxygen conditions, while GHK-Cu's own activity supports skin repair. Researchers reported the hydrogel showed antibacterial activity, promoted tissue repair, antioxidant capacity and new blood-vessel formation. These are laboratory and animal-model findings, mechanistic and formulation signals, not clinical evidence, and GHK-Cu is one functional component of a composite system rather than tested alone. This is a genuine (not sensor-analyte) use of GHK-Cu, relevant to its skin-repair evidence base, but human data would be needed before any clinical conclusion.
Materials today. Bion=—AnimalAug 1, 2026 - Study · GHK-CuWeak / none
Hierarchical regulation and mechanism of "open-hollow-fibrous network" structures: Osteogenic-angiogenic coupling responses of poly(γ-benzyl-L-glutamate) microspheres.
This is a materials-science and cell-culture (in-vitro) study, not a clinical investigation of GHK-Cu as an injectable peptide. GHK-Cu appears here as a bioactive coating chemically grafted onto porous polypeptide microspheres designed as scaffolds for bone repair. The researchers report that the copper-peptide-functionalised microspheres were cytocompatible and, compared with plain microspheres, increased mineralisation in bone-marrow mesenchymal stem cells and raised osteogenic gene expression (Runx2, OPN, and OCN by roughly 1.6- to 3.5-fold), alongside signs of blood-vessel formation in a tube-formation assay. Those are coherent signals consistent with copper's known role in matrix and vascular biology, but they are cell-level readouts in an engineered material - not evidence that GHK-Cu builds bone in a living body, still less in humans. These are preclinical findings; human data would be needed before clinical conclusions could be drawn. Weight this as scaffold-engineering proof-of-concept where the peptide is one functional ingredient among several.
Biomaterials advancesn=—In vitroJun 15, 2026 - Study · GHK-CuWeak / none
Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs.
Two framing points matter most here. First, this is a preprint posted on Research Square - it has not yet been peer-reviewed, so its findings should be treated as provisional. Second, it is an animal study in aged mice, making it a mechanistic signal rather than clinical proof. Within those limits it is a genuinely interesting efficacy-and-mechanism study: aged mice given GHK-Cu either short-term intraperitoneally or longer-term intranasally both showed improved performance on a hippocampal-dependent spatial-learning task, but the two routes engaged strikingly different molecular programs on RNA sequencing - intranasal dosing suppressed growth and mitochondrial-metabolic signalling, while intraperitoneal dosing activated stress-response and DNA-repair pathways. The behavioural benefit was more consistent and sustained with the intranasal route. The takeaway that route and duration shape the biological response is a useful hypothesis. But this is unreplicated, not yet peer-reviewed, and in rodents; human cognitive data for GHK-Cu do not exist. Read it as an early lead, not a conclusion.
Research squaren=—AnimalMay 26, 2026 - Study · GHK-CuWeak / none
Glycyl-L-histidyl-L-lysine-Cu2+ (GHK-Cu) Attenuates CuSO4 or LPS induced-inflammation in Zebrafish larvae model.
This is a zebrafish-larva study of GHK-Cu's anti-inflammatory and antioxidant activity - an animal model, so a mechanistic signal rather than clinical proof, though zebrafish are a useful bridge above cell culture because inflammation can be watched in a living, transparent organism. Researchers chemically provoked acute inflammation with copper sulfate or LPS, then reported that GHK-Cu reduced the migration of immune cells (neutrophils and macrophages), lowered pro-inflammatory signals (tnf-a, il-1b, il6) while raising the anti-inflammatory il-10, cut nitric oxide and reactive-oxygen-species levels, boosted the antioxidant enzyme SOD, and downregulated the JAK1 pathway. This is a mechanistically detailed and internally consistent result that fits GHK-Cu's proposed antioxidant and tissue-repair biology, and the authors frame it modestly - as support for GHK-Cu as a cosmetic functional ingredient. The limits are the usual ones: larval fish are far from human physiology, and these are preclinical findings. Human data would be needed before clinical conclusions could be drawn. A solid mechanistic data point, not a therapeutic claim.
European journal of pharmacologyn=—AnimalMay 10, 2026 - Study · GHK-CuWeak / none
The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.
This is a laboratory study in Caenorhabditis elegans, a millimetre-long roundworm widely used as a first-pass model for ageing biology because its short lifespan and conserved stress-response pathways make it fast and tractable. It is a mechanistic screen, not clinical evidence. The researchers report that GHK-Cu extended the worms' lifespan and improved several age-related measures - stress resistance, movement, feeding and defecation rhythms, and reduced accumulation of ageing pigments - and that these effects tracked with better-preserved mitochondrial function and activation of the DAF-16 and SKN-1 pathways (worm counterparts of the FOXO and Nrf2 antioxidant-defence systems). That is a coherent story and consistent with GHK-Cu's proposed antioxidant activity. But the caveats are large: worms are separated from human physiology by an enormous evolutionary gap, lifespan-extension hits in C. elegans frequently fail to translate, and this is a single first report. These are preclinical findings; human data would be needed before any clinical conclusions could be drawn. Treat it as hypothesis-generating.
Biogerontologyn=—AnimalMay 5, 2026 - Study · GHK-CuWeak / none
The Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds.
This study belongs to analytical chemistry, not biology or medicine, and is only tangentially about GHK-Cu as a peptide of interest to this audience. The researchers report that GHK-Cu has 'laccase-like' catalytic activity - it can mimic an enzyme that oxidises phenolic compounds - and they exploit that property to build a low-cost colour-changing sensor for detecting substances like epinephrine and 2-aminophenol, including a smartphone-linked cotton-based test strip for seawater. The kinetic and detection-limit figures reported are a materials-science result about the copper complex as a catalyst, and say nothing about GHK-Cu's effects in living tissue, its wound-healing or cosmetic uses, or any clinical outcome. There is no biological model here, in vitro or otherwise, in the physiological sense. For readers tracking GHK-Cu's therapeutic evidence, this is essentially off-topic: interesting chemistry about the molecule's copper centre, but not evidence bearing on human use of any kind.
Biosensorsn=—In vitroApr 12, 2026 - Study · SS-31Weak / none
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
This narrative review in Sports Medicine surveys the pharmacological profiles, regulatory standing, and safety data for eleven peptides marketed to athletes and patients seeking injury recovery — ranging from FDA-approved tesamorelin to unapproved compounds such as BPC-157, TB-500, and MOTS-c. The authors' central finding is that a substantial regulatory gap exists: while some peptides (tesamorelin, sermorelin historically) have cleared rigorous approval processes for specific indications, many others circulate in a gray market supported primarily by animal-model data and amplified by social media. A narrative review design is worth flagging. Unlike a systematic review or meta-analysis, it does not involve exhaustive literature search protocols or pooled effect-size estimates, which means it reflects editorial judgment about which evidence to emphasise. That is appropriate for a broad landscape survey but limits the precision of any efficacy conclusions. The key caveat — which the authors acknowledge directly — is that favorable preclinical signals in rodent tissue-repair and metabolic models do not reliably translate to human outcomes. The review also raises an...
Sports medicine (Auckland, N.Z.)n=——Apr 12, 2026 - Study · GHK-CuWeak / none
Golgi-targeted copper delivery strategy via enhancing copper-dependent proteins' activity for fascia regeneration.
This is an engineering-focused study in cells and in a rabbit fascia-defect model, where GHK-Cu serves as a controlled, sustained copper source within a sophisticated delivery system rather than as a standalone therapeutic peptide. The core idea is to route copper specifically into the Golgi apparatus - by pairing GHK-Cu with lipid nanoparticles carrying mRNA for the copper chaperone ATOX1 - so that copper-dependent enzymes such as lysyl oxidase (LOX), which cross-links collagen, get properly activated. Researchers report the system raised Golgi copper, boosted LOX activity to 1.78 times control, and enhanced blood-vessel formation in vitro, and in rabbits promoted collagen alignment, new vessels, and better tissue reconstruction. It is a coherent, mechanistically grounded result that fits copper biology, but GHK-Cu's specific contribution is entangled with the mRNA and nanoparticle components, so credit belongs to the combined platform. These are preclinical findings; human data would be needed before clinical conclusions could be drawn.
Journal of controlled release : official journal of the Controlled Release Societyn=—AnimalFeb 10, 2026 - Study · GHK-CuWeak / none
Smart Healing for Wound Repair: Emerging Multifunctional Strategies in Personalized Regenerative Medicine and Their Relevance to Orthopedics.
This is a broad narrative review of next-generation wound-healing technologies - scaffolds, growth-factor hydrogels, smart electronic dressings, exosomes, 3D bioprinting, and more - written with an eye toward orthopaedic applications. GHK-Cu is not the subject here; it is named once, in passing, as an example of a bioactive peptide that can be incorporated into such platforms, alongside antimicrobial peptides and glycosaminoglycan mimetics. That distinction matters for how a reader should weight it: this is a mention, not a study of GHK-Cu, and it reports no new data, no experiment, and no outcome specific to the peptide. As a review it also carries the usual caveats - selective, non-systematic, and surveying a field still largely at the preclinical and device-development stage. For someone tracking the GHK-Cu evidence base, this contributes context - that the peptide is considered a candidate ingredient in advanced wound dressings - but no evidence of effect. Treat it accordingly.
Antibiotics (Basel, Switzerland)n=——Jan 1, 2026 - Study · TesamorelinWeak / none
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
This narrative review in the American Journal of Sports Medicine takes an appropriately cautious inventory of injectable peptide therapy for orthopaedic and sports medicine — a field where patient demand has outpaced clinical evidence considerably. The authors surveyed BPC-157, TB-4/TB-500, CJC-1295 plus ipamorelin, tesamorelin, and GHK-Cu via PubMed and found a consistent pattern: promising preclinical signals, thin or absent human data, and unresolved questions around dosing, frequency, and duration for every compound reviewed. The review's conclusions align well with the broader evidence landscape for these peptides. BPC-157's lone human data point is a methodologically limited case series. Tesamorelin, the most regulation-hardened compound in the group with FDA approval and Phase III RCT backing, earned that standing for HIV-associated lipodystrophy — a narrow indication with no orthopaedic carryover. The murine muscle data for CJC-1295 plus ipamorelin is mechanistically interesting but cannot be extrapolated to clinical use. As a narrative review, this paper synthesises existing literature rather than generating new data — it reflects the state of evidence rather than...
The American journal of sports medicinen=——Jan 1, 2026 - Study · DSIPWeak / none
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, surveys the mechanistic rationale for using therapeutic peptides — including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon — in orthopaedic and musculoskeletal contexts. As a narrative review, it synthesises existing literature rather than generating new data; it carries no experimental controls, no patient cohort, and no statistical analysis of outcomes. Readers should weight it as an expert-curated overview, not as clinical evidence. The review's own authors acknowledge the central limitation plainly: preclinical findings are promising, but clinical trials are currently lacking. That candid admission matters. For most peptides covered — BPC-157, TB-500, ipamorelin, and epitalon in particular — the mechanistic picture is built almost entirely on rodent and in-vitro models. Tesamorelin is the notable exception, carrying FDA approval for HIV-associated lipodystrophy on the basis of Phase III RCT data, though that evidence does not transfer to orthopaedic applications. The review is useful as a...
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsn=——Jan 1, 2026 - Study · TirzepatideWeak / none
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
This narrative review from Frontiers in Aging maps nine therapeutic peptides across aging-related domains — metabolic function, telomere biology, tissue repair, neuroprotection, GH modulation, and sexual function. The authors drew on 20 primary sources selected from PubMed, Scopus, and regulatory databases through January 2026. The core finding is an evidence stratification most readers of this space already sense: FDA-approved agents (tirzepatide, bremelanotide) rest on large-scale registration-quality trial data, while investigational peptides — epitalon, BPC-157, TB-500, Semax, GHK-Cu, CJC-1295, ipamorelin — show mechanistically interesting but methodologically limited signals, predominantly from preclinical models or small, often non-replicated studies. The critical caveat is the design itself. Narrative reviews are synthesis without meta-analytic rigour; the 20-source selection pool is modest for a field this broad, and the review does not appear to have applied formal quality-grading criteria. Conclusions therefore reflect the authors' judgment rather than a systematic evidence synthesis. For readers tracking investigational peptides: the review adds conceptual framing...
Frontiers in agingn=——Jan 1, 2026 - Study · GHK-CuWeak / none
An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant.
This is a biomaterials study, tested in cells and in an animal inflammation model, in which GHK-Cu is loaded onto hydroxyapatite microspheres to make an injectable soft-tissue filler with added anti-inflammatory and antioxidant properties. The rationale is practical: fillers can provoke inflammatory reactions, and here GHK-Cu is adsorbed onto the mineral microspheres to release slowly - reported over roughly seven days - and blunt that response. In an LPS-driven inflammation model in vitro and in vivo, researchers report the GHK-Cu-loaded gel lowered inflammatory factors and reactive oxygen species, raised the antioxidant enzyme SOD, and was associated with collagen deposition on tissue staining. The signals fit GHK-Cu's established local anti-inflammatory and matrix-supporting profile. Caveats: this is a combination material, so effects belong to the loaded filler rather than the peptide alone, and these are preclinical findings. Human data would be needed before clinical conclusions could be drawn. Read it as filler-formulation development, not human evidence.
Colloids and surfaces. B, Biointerfacesn=—In vitroDec 1, 2025 - Study · GHK-CuWeak / none
Copper Complexes with New Glycyl-l-histidyl-l-lysine-Hyaluronan Conjugates Show Antioxidant Properties and Osteogenic and Angiogenic Synergistic Effects.
This is an in-vitro chemistry and cell-biology study developing new conjugates of GHK with hyaluronic acid (GHK-HA), then complexing them with copper, to make the peptide more stable against degradation and oxidative or hydrolytic stress. It is a molecular-design and mechanism paper, not a clinical or even whole-animal study. Researchers report that the GHK-HA conjugate binds copper(II) and, in cell assays, enhances the two components' antioxidant activity and promotes release of trophic, angiogenic, and osteogenic factors including BDNF, VEGF, and BMP-2, with the effects linked to copper chaperones (CCS and Atox1) moving into the nucleus to act as transcription factors. The findings are coherent and fit copper's known role in matrix and vascular signalling, and the stabilisation rationale is sound. But these are cell-level readouts of a newly engineered molecule; they do not demonstrate bone regeneration in a living body, let alone in humans. These are preclinical findings; human data would be needed before clinical conclusions could be drawn.
Bioconjugate chemistryn=—In vitroApr 16, 2025 - Study · GHK-CuWeak / none
Palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in both A375 and B16 cell lines.
A cell-culture study reporting that a combination agent, palmitoyl GHK-copper plus acetyl tyrosine (CP-AcT), increased melanin production in two melanoma cell lines (human A375 and mouse B16) at concentrations that did not reduce cell viability, alongside increases in tyrosinase activity and melanin-pathway gene and protein expression. This is in-vitro work only; human data are needed before any clinical conclusions can be drawn. Two framing points matter. First, the melanin effect is driven substantially by the acetyl tyrosine and copper delivery, not by GHK-Cu's better-known collagen and skin-repair biology, so it should not be read across to GHK-Cu's cosmetic uses. Second, the cells used are melanoma (cancer) lines; a compound that raises melanin output in melanoma cells in a dish is a mechanistic observation, not a benefit, and says nothing about safety. For GHK-Cu readers this sits at the edge of the peptide's story, a pigment-pathway experiment, not evidence for the peptide's marketed skin or wound applications.
Biochemical and biophysical research communicationsn=—In vitroJan 1, 2025 - Study · GHK-CuWeak / none
Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?
This is a methodological review, and its value lies precisely in exposing a knowledge gap rather than claiming an effect. It examines whether we are even equipped to measure how well GHK-Cu - encapsulated in liposomes - permeates the skin. The framing is honest: GHK-Cu is credited with beneficial cosmetic properties (reducing fine lines, improving elasticity), but it is a fairly water-loving molecule that struggles to cross the skin's oily outer barrier, and liposome encapsulation is a proposed way to improve delivery. The review's conclusion is that the transport of liposome-encapsulated GHK-Cu has received little study, and it calls for better methods to assess it. For readers weighing GHK-Cu's topical case, this is a clarifying reminder that a central assumption - that the peptide actually reaches its site of action in the skin - remains under-measured. No efficacy or clinical outcomes are reported here; it is a review about measurement readiness, useful mainly for calibrating how much we do not yet know.
Molecules (Basel, Switzerland)n=——Jan 1, 2025 - Study · GHK-CuWeak / none
Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing.
This is a biomaterials study, largely in-vitro with wound-dressing characterisation, in which GHK-Cu is loaded into an all-natural self-healing hydrogel built from food-derived ingredients - oxidised konjac glucomannan and egg white - cross-linked through Schiff-base chemistry. The appeal is a low-cost, biocompatible, biodegradable dressing for infected wounds, with GHK-Cu added for its anti-inflammatory and repair-supporting properties. Researchers report the resulting gel showed antibacterial and anti-inflammatory behaviour, adhered to tissue to help stop bleeding, and encouraged new blood-vessel formation, positioning it as a candidate skin-regeneration dressing. As with the other hydrogel papers here, GHK-Cu's specific contribution is inseparable from the matrix, so any benefit belongs to the combined material. The evidence is also early-stage and mechanistic rather than clinical. These are preclinical findings; human data would be needed before clinical conclusions could be drawn. Useful as proof-of-concept for a sustainable dressing incorporating the peptide, not as evidence of the peptide's standalone effect.
Biomaterials researchn=—In vitroJan 1, 2025 - Study · GHK-CuWeak / none
Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.
This is a narrative review examining GHK - and its derivatives GHK-Cu and palmitoylated Pal-GHK - as topical anti-wrinkle ingredients, and it is unusually candid about the gap between marketing and evidence. The review affirms, from cell-culture data, that GHK stimulates collagen and glycosaminoglycan synthesis and supports nerve outgrowth and angiogenesis, which is why it is so widely promoted in cosmetics. But its central, useful observation is a limitation: despite GHK-Cu and Pal-GHK being ubiquitous in anti-wrinkle products, there is a 'surprising absence of clinical studies' using them, and GHK is quite hydrophilic, so whether enough of it actually permeates the lipophilic outer skin barrier to act at its target is an open question. The review surveys permeation-enhancement strategies (liposomes, chemical modification, cell-penetrating peptides, microneedling) as ways to address this. For readers: strong laboratory rationale, genuinely thin clinical and skin-penetration evidence. A well-balanced reference on where the topical GHK case is under-supported.
BioImpacts : BIn=——Jan 1, 2025 - Study · GHK-CuWeak / none
Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.
This is a mechanistically thorough efficacy study of GHK-Cu in a standard mouse model of ulcerative colitis (DSS-induced), backed by cell-culture and gene-silencing experiments - a genuine investigation of the peptide's effect and pathway, not a passing mention. Researchers report that GHK-Cu eased weight loss, improved disease-activity scores, reduced colon damage and inflammatory cytokines (TNF-a, IL-6, IL-1b), increased mucus-producing goblet cells, and restored tight-junction proteins (ZO-1, Occludin), and they trace much of this to upregulated SIRT1 and suppressed phosphorylated STAT3. Silencing STAT3 abolished the peptide's effect on epithelial healing, supporting a causal role for that pathway. This is a well-constructed preclinical package with convincing internal mechanistic logic. The essential limits: this is a mouse model of an induced disease, GHK-Cu here is given as an experimental agent, and there are no human trials for this indication. These are preclinical findings; human data would be needed before any clinical conclusions could be drawn. Read as a strong mechanistic lead in one animal model.
Frontiers in pharmacologyn=—AnimalJan 1, 2025 - Study · GHK-CuWeak / none
Novel Applications of CE-ICP-MS/MS: Monitoring of Antiaging GHK-Cu Cosmetic Component Encapsulation in Liposomes.
This is an analytical-chemistry study, and only incidentally about GHK-Cu as a peptide of biological interest. The researchers demonstrate a novel application of a hyphenated technique - capillary electrophoresis coupled to inductively coupled plasma tandem mass spectrometry (CE-ICP-MS/MS) - to monitor how well GHK-Cu is encapsulated inside liposomes, by tracking copper and phosphorus signals. It is a proof-of-concept for a measurement method, not a study of what GHK-Cu does in the body. The result - that the technique can confirm liposome formation and quantify the peptide's concentration inside them - is a genuine advance for cosmetic-formulation analysis, and it connects to the broader question of improving GHK-Cu's skin delivery. But it reports no biological model, no efficacy endpoint, and no clinical outcome. For a reader tracking GHK-Cu's therapeutic or cosmetic evidence, this contributes a tool for quality-controlling formulations, nothing about effect. Read it as laboratory instrumentation work adjacent to the peptide, not evidence for its use.
Electrophoresisn=——Nov 1, 2024 - Study · GHK-CuWeak / none
The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.
This is a mechanistically focused animal-and-cell study of GHK-Cu in silicosis - the incurable, progressive lung scarring caused by chronic crystalline-silica exposure, for which no specific drug exists. That unmet need makes any lead noteworthy, but the evidence stage must be kept clear. In a mouse silicosis model and in RAW264.7 macrophages, researchers report that GHK-Cu reduced lung inflammation and fibrosis, and they identify peroxiredoxin 6 (PRDX6) as a molecular target the peptide binds, with the benefit linked to dampened silica-induced oxidative stress in alveolar macrophages. Notably, they report this occurred 'without significant systemic toxicity' in the model. The target-identification work adds mechanistic credibility beyond a simple observed effect. But this is an induced disease in mice plus a macrophage cell line - a mechanistic signal, not clinical proof - and there are no human data for GHK-Cu in lung disease. These are preclinical findings; human data would be needed before any clinical conclusions could be drawn. A promising but early mechanistic lead.
Redox biologyn=—AnimalSep 1, 2024 - Study · GHK-CuWeak / none
An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults.
This is a small, open-label, single-centre study of a multi-ingredient scalp regimen for mild-to-moderate dandruff and seborrheic-type flaking, and its design places firm limits on what it can tell us about GHK-Cu specifically. The tested products combined a hydroxy-acid exfoliating scrub with a serum containing copper tripeptide-1 (GHK-Cu) plus witch hazel, hesperidin, hyaluronic acid, and pea protein - so any benefit is attributable to the whole regimen, not the peptide alone. Over 15 days the researchers report statistically significant improvements: adherent scalp flaking fell about 61%, scalp hydration rose about 76%, and measured hair density and thickness increased, with all participants reporting satisfaction. Because there was no control or placebo group and the study was open-label with a short 15-day window and multiple active ingredients, the results are susceptible to expectation effects, regression to the mean, and confounding between components. No serious adverse events were reported. Read this as preliminary, real-world tolerability-and-satisfaction data on a combination product, not as evidence for GHK-Cu on its own.
Cureusn=—HumanSep 1, 2024 - Study · GHK-CuWeak / none
Rigid-flexible nanocarriers loaded with active peptides for antioxidant and anti-inflammatory applications in skin.
This is an in-vitro formulation study, not an efficacy trial. Researchers encapsulated GHK-Cu in a polyol-modified liposomal nanocarrier and reported improved loading, stability, resistance to enzymatic degradation and slower peptide release in cell-based assays; the system was reported to modulate Nrf2, SIRT1 and COX-2 signalling and to reduce markers of oxidative inflammation, senescence and apoptosis in cultured cells. The primary contribution is delivery engineering — it addresses GHK-Cu's practical instability rather than testing a clinical outcome. GHK-Cu already has its strongest evidence in topical cosmetic contexts, and these cell-culture signals are consistent with that landscape but do not extend it. No skin, animal or human endpoints were measured here. These are preclinical, in-vitro findings; human data are needed before clinical conclusions can be drawn. The abstract's ‘non-toxic’ framing refers to the cell system studied, not to human safety.
Colloids and surfaces. B, Biointerfacesn=—In vitroApr 1, 2024